Fluicell AB (publ) (FLUI.ST)
SEK 0.04
(0.5%)
SEK 0.04
(0.5%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.73 Million SEK | -1188.56% |
| 2022 | 2.58 Million SEK | 37.15% |
| 2021 | 1.88 Million SEK | -48.26% |
| 2020 | 3.64 Million SEK | 78.34% |
| 2019 | 2.04 Million SEK | 144.91% |
| 2018 | 835 Thousand SEK | 111.22% |
| 2017 | -7.44 Million SEK | -50.1% |
| 2016 | -4.95 Million SEK | -28.81% |
| 2015 | -3.84 Million SEK | -4513.19% |
| 2014 | 87.21 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -8.01 Million SEK | 5.08% |
| 2024 Q2 | -5.58 Million SEK | 101.91% |
| 2023 Q3 | -270 Thousand SEK | -134.97% |
| 2023 Q4 | -8.44 Million SEK | -3028.52% |
| 2023 Q2 | 772 Thousand SEK | -47.3% |
| 2023 FY | -28.17 Million SEK | -1188.56% |
| 2023 Q1 | 1.46 Million SEK | 36.28% |
| 2022 Q4 | 1.07 Million SEK | 151.76% |
| 2022 FY | 2.58 Million SEK | 37.15% |
| 2022 Q3 | 427 Thousand SEK | -0.7% |
| 2022 Q2 | 430 Thousand SEK | -34.55% |
| 2022 Q1 | 657 Thousand SEK | 26.59% |
| 2021 Q3 | 646 Thousand SEK | 105.08% |
| 2021 Q4 | 519 Thousand SEK | -19.66% |
| 2021 FY | 1.88 Million SEK | -48.26% |
| 2021 Q1 | 406 Thousand SEK | -62.85% |
| 2021 Q2 | 315 Thousand SEK | -22.41% |
| 2020 Q3 | -32 Thousand SEK | -101.98% |
| 2020 Q4 | 1.09 Million SEK | 3515.63% |
| 2020 Q1 | 972 Thousand SEK | 59.08% |
| 2020 FY | 3.64 Million SEK | 78.34% |
| 2020 Q2 | 1.61 Million SEK | 66.05% |
| 2019 Q3 | 395 Thousand SEK | -16.31% |
| 2019 Q4 | 611 Thousand SEK | 54.68% |
| 2019 FY | 2.04 Million SEK | 144.91% |
| 2019 Q1 | 566 Thousand SEK | 217.98% |
| 2019 Q2 | 472 Thousand SEK | -16.61% |
| 2018 Q1 | 152 Thousand SEK | -68.53% |
| 2018 Q4 | 178 Thousand SEK | -2.73% |
| 2018 Q3 | 183 Thousand SEK | -43.17% |
| 2018 Q2 | 322 Thousand SEK | 111.84% |
| 2018 FY | 835 Thousand SEK | 111.22% |
| 2017 Q4 | 483 Thousand SEK | 719.23% |
| 2017 FY | -7.44 Million SEK | -50.1% |
| 2017 Q1 | 46 Thousand SEK | 116.91% |
| 2017 Q2 | 14 Thousand SEK | -69.57% |
| 2017 Q3 | -78 Thousand SEK | -657.14% |
| 2016 Q4 | -272 Thousand SEK | 0.0% |
| 2016 FY | -4.95 Million SEK | -28.81% |
| 2015 FY | -3.84 Million SEK | -4513.19% |
| 2014 FY | 87.21 Thousand SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 101.082% |
| Ziccum AB (publ) | -23.28 Million SEK | 107.464% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 99.498% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 95.841% |
| Mendus AB (publ) | 28.48 Million SEK | 93.899% |
| Genovis AB (publ.) | 54 Million SEK | 96.782% |
| Intervacc AB (publ) | -13.79 Million SEK | 112.6% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 19.945% |
| Active Biotech AB (publ) | -1.67 Million SEK | 203.761% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 82.555% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 93.52% |
| Aptahem AB (publ) | 2.63 Million SEK | 33.933% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 150.804% |
| Kancera AB (publ) | -1.96 Million SEK | 188.448% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -2157.143% |
| Saniona AB (publ) | 11.78 Million SEK | 85.247% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 133.965% |
| Biovica International AB (publ) | 6.87 Million SEK | 74.727% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 107.465% |
| AcouSort AB (publ) | 8.38 Million SEK | 79.282% |
| Xintela AB (publ) | 78 Thousand SEK | -2128.205% |
| Abliva AB (publ) | -35.66 Million SEK | 104.873% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 101.183% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 38.083% |
| OncoZenge AB (publ) | 3000.00 SEK | -57833.333% |
| Amniotics AB (publ) | -1.93 Million SEK | 190.052% |
| 2cureX AB (publ) | -37.48 Million SEK | 104.636% |
| CombiGene AB (publ) | -21.29 Million SEK | 108.163% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 510.875% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 99.846% |
| Camurus AB (publ) | 1.58 Billion SEK | 99.89% |
| Corline Biomedical AB | 28.38 Million SEK | 93.876% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 101.416% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 105.05% |
| I-Tech AB | 27.56 Million SEK | 93.695% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 97.55% |
| Cyxone AB (publ) | 2.61 Million SEK | 33.435% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 48.927% |
| Biosergen AB | -456 Thousand SEK | 481.14% |
| Cantargia AB (publ) | -3.45 Million SEK | 150.362% |
| NextCell Pharma AB | -43.74 Million SEK | 103.973% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 118.904% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 84.507% |
| Nanologica AB (publ) | -76 Thousand SEK | 2386.842% |
| SynAct Pharma AB | -778 Thousand SEK | 323.393% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 1000.518% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 113.45% |
| Lipum AB (publ) | 53 Thousand SEK | -3179.245% |
| BioInvent International AB (publ) | 71.46 Million SEK | 97.568% |
| Alzinova AB (publ) | 19.87 Million SEK | 91.255% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 95.212% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -18.795% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 11686.667% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -4.825% |
| Simris Alg AB (publ) | 2 Million SEK | 13.403% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 148.547% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 95.089% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 265.682% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 44.526% |